[Prevalence of response to anti-HBV infection in patients on maintenance hemodialysis infected with hepatitis C virus (HCV)].
We have studied the antibody response to hepatitis B vaccine in 42 hemodialysis patients; 8 of them were diagnosed as having HCV infection before vaccination. Hemodialysis patients received four doses of recombinant HB vaccine (Engerix-B, SKB, 40 micrograms per dose). Seroconversion occurred in 71.4% of all hemodialysis patients; in 79.4% of HCV-negative and in 37.5% of HCV-positive patients. Effective immunity (anti-HBs titer higher than 100 m IU/ml) was observed in 12.5% of HCV positive and in 35.3% of HCV-negative patients. We conclude that HCV infection may modify or postpone the response to hepatitis B vaccine.
Muszytowski
M
M
Z Ośrodka Dializ Wojewódzkiego, Szpitala Zespolonego w Toruniu.
Manitius
J
J
Ruszkiewicz-Fołda
M
M
D000328:Adult; D005260:Female; D006510:Hepatitis B Antibodies / Q000032:analysis; D017325:Hepatitis B Vaccines / Q000276:immunology*; D006526:Hepatitis C / Q000276:immunology* / Q000517:prevention & control; D006801:Humans; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis
D006510:Hepatitis B Antibodies; D017325:Hepatitis B Vaccines
Wystepowanie odpowiedzi na szczepienie przeciwko HBV u chorych przewlekle hemodializowanych i zakazonych wirusem C (HCV).